Rob Myers

895 total citations
20 papers, 363 citations indexed

About

Rob Myers is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Rob Myers has authored 20 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 17 papers in Hepatology and 4 papers in Surgery. Recurrent topics in Rob Myers's work include Liver Disease Diagnosis and Treatment (16 papers), Hepatitis C virus research (11 papers) and Hepatitis B Virus Studies (10 papers). Rob Myers is often cited by papers focused on Liver Disease Diagnosis and Treatment (16 papers), Hepatitis C virus research (11 papers) and Hepatitis B Virus Studies (10 papers). Rob Myers collaborates with scholars based in France, United States and Italy. Rob Myers's co-authors include Thierry Poynard, John G. McHutchison, Janice K. Albrecht, M.P. Manns, Stephen Pianko, Keyur Patel, Vincent Thibault, Vlad Ratziu, B. Mccolgan and Anuj Gaggar and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Diabetes.

In The Last Decade

Rob Myers

18 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rob Myers France	9	327	311	25	23	18	20	363
Fernanda Branco Brazil	8	165 0.5×	163 0.5×	29 1.2×	34 1.5×	14 0.8×	11	252
S. Lobello Italy	8	579 1.8×	572 1.8×	20 0.8×	26 1.1×	20 1.1×	16	630
Vassilios Sevastianos Greece	7	399 1.2×	364 1.2×	17 0.7×	27 1.2×	21 1.2×	23	459
Chang Don Lee South Korea	12	304 0.9×	291 0.9×	16 0.6×	53 2.3×	17 0.9×	36	390
Namiki Izumi Japan	9	241 0.7×	284 0.9×	28 1.1×	16 0.7×	21 1.2×	17	328
G. Raimondo Italy	10	216 0.7×	220 0.7×	24 1.0×	27 1.2×	12 0.7×	23	296
Waleed Al–Hamoudi Saudi Arabia	14	362 1.1×	322 1.0×	23 0.9×	26 1.1×	21 1.2×	29	424
Jui-Ting Hu Taiwan	8	382 1.2×	325 1.0×	22 0.9×	40 1.7×	17 0.9×	10	417
Ming‐Yen Hsieh Taiwan	6	213 0.7×	245 0.8×	22 0.9×	11 0.5×	12 0.7×	13	284
Yanjie Ren Qatar	8	181 0.6×	191 0.6×	35 1.4×	22 1.0×	14 0.8×	13	308

Countries citing papers authored by Rob Myers

Since Specialization

Citations

This map shows the geographic impact of Rob Myers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Myers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Myers more than expected).

Fields of papers citing papers by Rob Myers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob Myers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Myers. The network helps show where Rob Myers may publish in the future.

Co-authorship network of co-authors of Rob Myers

This figure shows the co-authorship network connecting the top 25 collaborators of Rob Myers. A scholar is included among the top collaborators of Rob Myers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob Myers. Rob Myers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peng, Zhenwei, Guangyan Wei, Pinzhu Huang, et al.. (2024). ASK1/p38 axis inhibition blocks the release of mitochondrial “danger signals” from hepatocytes and suppresses progression to cirrhosis and liver cancer. Hepatology. 80(2). 346–362. 7 indexed citations

Iyer, Janani, Quang Bao Le, Rob Myers, et al.. (2022). Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 77. S700–S701. 2 indexed citations

Younossi, Zobair M., Quentin M. Anstee, Michael Trauner, et al.. (2020). 1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). Diabetes. 69(Supplement_1).

Myers, Rob, Biao Li, Zhaoshi Jiang, et al.. (2020). Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. Liver International. 40(7). 1693–1700. 11 indexed citations

Poynard, Thierry, Valentina Peta, M. Munteanu, et al.. (2018). The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology & Hepatology. 31(3). 393–402. 15 indexed citations

Middleton, Michael S., Eric Lawitz, Saumya Jayakumar, et al.. (2017). Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial. Journal of Hepatology. 66(1). S668–S668. 1 indexed citations

Levy, Carlos Emílio, Christopher L. Bowlus, B. Mccolgan, et al.. (2017). Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. Journal of Hepatology. 66(1). S73–S73. 9 indexed citations

Levy, Carol J., Bertus Eksteen, M. Shiffman, et al.. (2017). Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S360–S361. 2 indexed citations

Bowlus, Christopher L., Krish Patel, Gideon M. Hirschfield, et al.. (2017). Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S359–S359. 4 indexed citations

10.

Sanyal, A., Manal F. Abdelmalek, Stephen H. Caldwell, et al.. (2017). Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials. Journal of Hepatology. 66(1). S54–S54. 20 indexed citations

11.

Myers, Rob. (2014). Interactive art and embodiment: The implicit body as performance, Nathaniel Stern : book review. 2014(89). 97–100.

12.

Grebely, Jason, Marc Bilodeau, Jordan J. Feld, et al.. (2013). The Second Canadian Symposium on Hepatitis C Virus: A Call to Action. SHILAP Revista de lepidopterología. 27(11). 627–632. 15 indexed citations

13.

Sherman, Morris, Alnoor Ramji, Susan Greenbloom, et al.. (2011). Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa‐2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Alimentary Pharmacology & Therapeutics. 35(1). 37–47. 9 indexed citations

14.

Marcellin, Patrick, Henry Lik‐Yuen Chan, Ching‐Lung Lai, et al.. (2007). [508] IN HEPATITIS B PATIENTS TREATED WITH EITHER ADEFOVIR OR TELBIVUDINE, MAXIMAL EARLY HBV SUPPRESSION AT 24 WEEKS PREDICTS OPTIMAL ONE-YEAR EFFICACY. Journal of Hepatology. 46. S193–S193. 3 indexed citations

15.

Marcellin, Patrick, Henry Lik‐Yuen Chan, Ching‐Lung Lai, et al.. (2007). [124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE. Journal of Hepatology. 46. S55–S55. 6 indexed citations

16.

Chan, Henry Lik‐Yuen, Ching‐Lung Lai, Jenny Heathcote, et al.. (2006). 52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis. Journal of Hepatology. 44. S24–S25. 8 indexed citations

17.

Cacoub, P., Isabelle Goderel, Philippe Morlat, et al.. (2005). Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiology and Infection. 133(2). 305–314. 8 indexed citations

18.

Myers, Rob, Vincent Thibault, & Thierry Poynard. (2003). The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis. 10(2). 103–110. 10 indexed citations

19.

Myers, Rob, Keyur Patel, Stephen Pianko, Thierry Poynard, & John G. McHutchison. (2003). The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. Journal of Viral Hepatitis. 10(1). 16–22. 39 indexed citations

20.

Poynard, Thierry, John G. McHutchison, M.P. Manns, Rob Myers, & Janice K. Albrecht. (2003). Biochemical Surrogate Markers of Liver Fibrosis and Activity in A Randomized Trial of Peginterferon Alfa–2B and Ribavirin. Hepatology. 38(2). 481–492. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact